Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats

Journal of Hepatology

Volumn 64, Issue 5, 2016, Pages 1049-1057

  Úbeda, María ^a,b   Lario, Margaret ^a,b   Muñoz, Leticia ^a,b   Borrero, María José ^a,b   Rodríguez Serrano, Macarena ^c   Sánchez Díaz, Ana María ^c   Del Campo, Rosa ^c   Lledó, Lourdes ^a   Pastor, Óscar ^c   García Bermejo, Laura ^c   Díaz, David ^a,b,d   Álvarez Mon, Melchor ^a,b,d   Albillos, Agustín ^a,b,c  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Ascites; Dysbiosis; Inflammation; Permeability

Indexed keywords

ALBUMIN; ANGIOGENIN; ANGIOGENIN 1; CYTOKINE; DEFENSIN; HETERODIMER; OBETICHOLIC ACID; OCCLUDIN; POLYPEPTIDE ANTIBIOTIC AGENT; TIGHT JUNCTION PROTEIN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; ZONULIN 1; CHENODEOXYCHOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; ASCITES; BACTERIAL LOAD; BACTERIAL TRANSLOCATION; CELL INFILTRATION; CONTROLLED STUDY; CYTOMETRY; ENTERITIS; FARNESOID X RECEPTOR ASSOCIATED GENE; GENE; GENE EXPRESSION; ILEUM; ILEUM MUCOSA; IMMUNOCOMPETENT CELL; INFLAMMATORY INFILTRATE; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MESENTERY LYMPH NODE; MICROFLORA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYROSEQUENCING; RAT; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; INFLAMMATION; INTESTINE; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; MICROBIOLOGY; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CHENODEOXYCHOLIC ACID; CYTOKINES; INFLAMMATION; INTESTINES; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84963647487     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.12.010     Document Type: Article

References (36)

1. R. Wiest, M. Lawson, and M. Geuking Pathological bacterial translocation in liver cirrhosis J Hepatol 60 2014 197 209
2. A. Albillos, M. Lario, and M. Alvarez-Mon Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance J Hepatol 61 2014 1385 1396
3. J. Du Plessis, H. Vanheel, C.E. Janssen, L. Roos, T. Slavik, P.I. Stivaktas, and et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function J Hepatol 58 2013 1125 1132
4. M. Perez-Paramo, J. Munoz, A. Albillos, I. Freile, F. Portero, M. Santos, and et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites Hepatology 31 2000 43 48
5. Z. Teltschik, R. Wiest, J. Beisner, S. Nuding, C. Hofmann, J. Schoelmerich, and et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense Hepatology 55 2012 1154 1163
6. L. Muñoz, M. Jose Borrero, M. Ubeda, M. Lario, D. Diaz, R. Frances, and et al. Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis Hepatology 56 2012 1861 1869
7. J.S. Bajaj, D.M. Heuman, P.B. Hylemon, A.J. Sanyal, M.B. White, P. Monteith, and et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications J Hepatol 60 2014 940 947
8. A.W. Yan, D.E. Fouts, J. Brandl, P. Starkel, M. Torralba, E. Schott, and et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease Hepatology 53 2011 96 105
9. N. Qin, F. Yang, A. Li, E. Prifti, Y. Chen, L. Shao, and et al. Alterations of the human gut microbiome in liver cirrhosis Nature 513 2014 59 64
10. P. Vavassori, A. Mencarelli, B. Renga, E. Distrutti, and S. Fiorucci The bile acid receptor FXR is a modulator of intestinal innate immunity J Immunol 183 2009 6251 6261
11. T. Inagaki, A. Moschetta, Y.K. Lee, L. Peng, G. Zhao, M. Downes, and et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor Proc Natl Acad Sci U S A 103 2006 3920 3925
12. L. Verbeke, R. Farre, B. Verbinnen, K. Covens, T. Vanuytsel, J. Verhaegen, and et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats Am J Pathol 185 2015 409 419
13. R.W. Parks, W.D. Clements, M.G. Smye, C. Pope, B.J. Rowlands, and T. Diamond Intestinal barrier dysfunction in clinical and experimental obstructive jaundice and its reversal by internal biliary drainage Br J Surg 83 1996 1345 1349
14. V. Lorenzo-Zuniga, R. Bartoli, R. Planas, A.F. Hofmann, B. Vinado, L.R. Hagey, and et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats Hepatology 37 2003 551 557
15. G. Kakiyama, P.B. Hylemon, H. Zhou, W.M. Pandak, D.M. Heuman, D.J. Kang, and et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis Am J Physiol Gastrointest Liver Physiol 306 2014 G929 G937
16. W.E. Naugler Bile acid flux is necessary for normal liver regeneration PLoS One 9 2014 e97426
17. R. Pellicciari, G. Costantino, E. Camaioni, B.M. Sadeghpour, A. Entrena, T.M. Willson, and et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid J Med Chem 47 2004 4559 4569
18. R.M. Gadaleta, K.J. van Erpecum, B. Oldenburg, E.C. Willemsen, W. Renooij, S. Murzilli, and et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease Gut 60 2011 463 472
19. P. Hartmann, P. Chen, H.J. Wang, L. Wang, D.F. McCole, K. Brandl, and et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice Hepatology 58 2013 108 119
20. L.V. Hooper, D.R. Littman, and A.J. Macpherson Interactions between the microbiota and the immune system Science 336 2012 1268 1273
21. L. Muñoz, A. Albillos, M. Nieto, E. Reyes, L. Lledo, J. Monserrat, and et al. Mesenteric Th1 polarization and monocyte TNF-alpha production: first steps to systemic inflammation in rats with cirrhosis Hepatology 42 2005 411 419
22. M. Ubeda, L. Muñoz, M.J. Borrero, D. Diaz, R. Frances, J. Monserrat, and et al. Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis Hepatology 52 2010 2086 2095
23. H. Kuribayashi, M. Miyata, H. Yamakawa, K. Yoshinari, and Y. Yamazoe Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling Eur J Pharmacol 697 2012 132 138
24. Y. Chen, F. Yang, H. Lu, B. Wang, D. Lei, Y. Wang, and et al. Characterization of fecal microbial communities in patients with liver cirrhosis Hepatology 54 2011 562 572
25. G. Garcia-Tsao, F.Y. Lee, G.E. Barden, R. Cartun, and A.B. West Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites Gastroenterology 108 1995 1835 1841
26. L. Muñoz, M.J. Borrero, M. Ubeda, M. Lario, D. Diaz, E. Aguado-Fraile, and et al. Commensal bacteria drives the expansion of proinflammatory T-lymphocytes in the small intestinal mucosa and worsens the epithelial barrier function in CCl4 cirrhotic rats with ascitis J Hepatol 60 2014 S76 (abstract P29)
27. T.T. Macdonald, and G. Monteleone Immunity, inflammation, and allergy in the gut Science 307 2005 1920 1925
28. J. Verdier, B. Begue, N. Cerf-Bensussan, and F.M. Ruemmele Compartmentalized expression of Th1 and Th17 cytokines in pediatric inflammatory bowel diseases Inflamm Bowel Dis 18 2012 1260 1266
29. M. Ubeda, M. Lario, L. Munoz, D. Diaz, M.J. Borrero, L. Garcia-Bermejo, and et al. Systemic inflammation in absence of gut bacterial translocation in C57BL/6 mice with cirrhosis Gut 62 2013 330 331
30. A. Hakansson, and G. Molin Gut microbiota and inflammation Nutrients 3 2011 637 682
31. A. Albillos, M. Nieto, M. Ubeda, L. Munoz, B. Fraile, E. Reyes, and et al. The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis Gut 59 2010 943 952
32. S. Fiorucci, E. Antonelli, G. Rizzo, B. Renga, A. Mencarelli, L. Riccardi, and et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis Gastroenterology 127 2004 1497 1512
33. S. Fiorucci, G. Rizzo, E. Antonelli, B. Renga, A. Mencarelli, L. Riccardi, and et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor g contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis J Pharmacol Exp Ther 315 2005 58 68
34. B. Schnabl, and D.A. Brenner Interactions between the intestinal microbiome and liver diseases Gastroenterology 146 2014 1513 1524
35. P. Fickert, A. Fuchsbichler, T. Moustafa, M. Wagner, G. Zollner, E. Halilbasic, and et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts Am J Pathol 175 2009 2392 2405
36. S. Cipriani, A. Mencarelli, G. Palladino, and S. Fiorucci FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats J Lipid Res 51 2010 771 784